Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Dr David Stamler’s Biotech Showcase Presentation

January 7, 2019 Kerry Rowe

Prana Biotechnology BSC Presntation 20180107 FINAL

Post navigation

Prana Presents at Biotech Showcase

Prana receives Orphan Designation for PBT434 for treatment of MSA

Related Posts

Prana receives $6.5 million R&D Tax Incentive Refund

May 9, 2016

Alterity’s lead drug candidate receives positive opinion from European medical agency

November 18, 2019November 18, 2019

Prana’s Alzheimer’s Disease Treatment Strategy Validated by Independent Study

March 6, 2014

Recent Posts

Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Alterity receives a $4.8 million R&D Tax Incentive Refund
European Commission approves Orphan Designation for Alterity’s lead drug candidate
Chairman’s Address to Shareholders 2019 Annual General Meeting
AGM 2019 Presentation

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News
Contact us

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065